depressive disorders

Improving the Cost-Effectiveness of a Healthcare System for Depressive Disorders by Implementing Telemedicine: A Health Economic Modeling Study.

Published June 15, 2013

Improving the Cost-Effectiveness of a Healthcare System for Depressive Disorders by Implementing Telemedicine: A Health Economic Modeling Study.

Am J Geriatr Psychiatry. 2013 Jun 4;
Lokkerbol J, Adema D, Cuijpers P, Reynolds CF, Schulz R, Weehuizen R, Smit F… Continue reading →

Measurement of Specific Medical School Stress: Translation of the “Perceived Medical School Stress Instrument” to the German Language.

Published June 6, 2013

Measurement of specific medical school stress: translation of the “Perceived Medical School Stress Instrument” to the German language.

GMS Z Med Ausbild. 2013; 30(2): Doc22
Kötter T, Voltmer E

Objective: Medical students encounter specific stressors during their studies. As… Continue reading →

Assessment of Behavior Abnormalities of Corticosteroids in Children With Nephrotic Syndrome.

Published June 6, 2013

Assessment of behavior abnormalities of corticosteroids in children with nephrotic syndrome.

ISRN Psychiatry. 2013; 2013: 921253
Youssef DM, Abdelsalam MM, Abozeid AM, Youssef UM

Introduction. The objective of this work was to define the frequency and severity of steroid… Continue reading →

Breaking Worse: The Emergence of Krokodil and Excessive Injuries Among People Who Inject Drugs in Eurasia.

Published June 4, 2013

Breaking worse: The emergence of krokodil and excessive injuries among people who inject drugs in Eurasia.

Int J Drug Policy. 2013 May 30;
Grund JP, Latypov A, Harris M

BACKGROUND: Krokodil, a homemade injectable opioid, gained its moniker from… Continue reading →

Effectiveness of Miltefosine Treatment in Targeting Anti-Leishmanial HO-1/Nrf-2-Mediated Oxidative Responses in Visceral Leishmaniasis Patients.

Published June 4, 2013

Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.

J Antimicrob Chemother. 2013 May 31;
Das S, Pandey K, Rabidas VN, Mandal A, Das P

OBJECTIVES: Miltefosine, an alkylphosphocholine anti-cancer drug, exhibits direct activity… Continue reading →

[Psychosomatic Relationships in Postmenopausal Women].

Published May 31, 2013

[Psychosomatic relationships in postmenopausal women].

Ter Arkh. 2013; 85(3): 86-9

To study the prevalence of depressive and anxiety disorders in postmenopausal disorders and their relationship with the manifestations of climacteric syndrome.The study enrolled 203 women, including 142 patients with… Continue reading →

Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-Based Care for the Treatment of Major Depressive Disorder.

Published May 29, 2013

Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-based Care for the Treatment of Major Depressive Disorder.

CNS Drugs. 2013 May 25;
Patkar AA, Pae CU

There is a growing body of evidence that supports the use of atypical… Continue reading →

Interplay Between Pro-Inflammatory Cytokines and Growth Factors in Depressive Illnesses.

Published May 16, 2013

Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses.

Front Cell Neurosci. 2013; 7: 68
Audet MC, Anisman H

The development of depressive disorders had long been attributed to monoamine variations, and pharmacological treatment strategies likewise focused on… Continue reading →

Mitochondrial Dysfunction, Oxidative Stress, and Major Depressive Disorder.

Published May 8, 2013

Mitochondrial dysfunction, oxidative stress, and major depressive disorder.

Neuropsychiatr Dis Treat. 2013; 9: 567-73
Tobe EH

There is controversy about depression being a physical illness, in part because a reproducible, sensitive, and specific biologic marker is not available. However,… Continue reading →

Placental Serotonin: Implications for the Developmental Effects of SSRIs and Maternal Depression.

Published May 1, 2013

Placental serotonin: implications for the developmental effects of SSRIs and maternal depression.

Front Cell Neurosci. 2013; 7: 47
Velasquez JC, Goeden N, Bonnin A

In addition to its role in the pathophysiology of numerous psychiatric disorders, increasing evidence points… Continue reading →